LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer (Q38206271)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2014

Language	Label	Description	Also known as
English	LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer	scientific article published on March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

31 August 2017

LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer (English)

1 reference

Europe PubMed Central

31 August 2017

author name string

Jens Köhler

1

1 reference

Europe PubMed Central

31 August 2017

Martin Schuler

2

1 reference

Europe PubMed Central

31 August 2017

language of work or name

0 references

publication date

1 March 2014

1 reference

Europe PubMed Central

31 August 2017

Future Oncology

1 reference

Europe PubMed Central

31 August 2017

10

1 reference

Europe PubMed Central

31 August 2017

4

1 reference

Europe PubMed Central

31 August 2017

533-540

1 reference

Europe PubMed Central

31 August 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Diarrhea associated with afatinib: an oral ErbB family blocker

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.9

21 January 2018

Identifiers

10.2217/FON.14.9

1 reference

Europe PubMed Central

31 August 2017

1 reference

Europe PubMed Central

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38206271&oldid=2116729987"